c ebpβ-lip drug

c ebpβ-lip drug Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module C/EBPβ: A transcription factor associated

Name: c ebpβ-lip drug Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module C/EBPβ: A transcription factor associated
Brand: hgidocs.co
SKU: 60808376535
Price: 29.78 USD
Availability: InStock
Rating: 4.1332 (7 reviews)

C EBP: A transcription factor associated with the irreversible progression of Alzheimer's disease Yao 2024 CNS Neuroscience & Therapeutics Wiley Online Library Purified anti C EBP beta 3 isoforms C EBP beta, LAP, LIP Antibody anti C EBP beta 1H7 C EBP LIP induces cancer type metabolic reprogramming by regulating the let 7 LIN28B circuit in mice Communications Biology A) Domain organization of C EBP family members. Each C EBP protein Download Scientific Diagram C EBP LIP mediated activation of the malate aspartate shuttle sensitizes cells to glycolysis inhibition ScienceDirect

SKU: 60808376535 · From hgidocs.co

4.1

USD29.78 USD53.78

Pay in 4 interest-free payments of $7.45 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Jul 31 - Aug 5

Description

& de Boer, R

c ebp-lip drug Natural Products with Antitumor Potential Targeting the MYB-C/EBP-p300 Transcription Module C/EBP: A transcription factor associated

Jart Prejuvenation Firming Bakuchiol Serum for Preventative Aging Water/Aqua/Eau, Butylene Glycol, Dipropylene Glycol, Glycerin, Propanediol, 1,2-Hexanediol, Dimethicone Crosspolymer, Bakuchiol, Vinyl Dimethicone, Hydrolyzed Collagen, Ethylhexylglycerin, Allantoin, Biosaccharide Gum-1, Dipotassium Glycyrrhizate, Adenosine, Sodium Dilauramidoglutamide Lysine, Hydrogenated Lecithin, Sodium Polyacryloyldimethyl Taurate, Isododecane, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Tromethamine, Fragrance (Parfum), Disodium EDTA, Tocopherol, Phenoxyethanol, Sodium Benzoate, Red 4 (CI 14700), Blue 1 (CI 42090)

S.WangJ.YannieP

Application Information for New Medical Services or Technologies Applicants for add-on payments for new medical services or technologies for FY 2025 must submit a formal request, including a full description of the clinical applications of the medical service or technology and the results of any clinical evaluations demonstrating that the new medical service or technology represents a substantial clinical improvement (unless the application is under one of the alternative pathways as previously described), along with a significant sample of data to demonstrate that the medical service or technology meets the high-cost threshold